Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on scPharmaceuticals (SCPH – Research Report), Andlauer Healthcare Group (ANDHF – Research Report) and Roche Holding AG (RHHVF – Research Report).
scPharmaceuticals (SCPH)
Maxim Group analyst Naz Rahman reiterated a Buy rating on scPharmaceuticals yesterday and set a price target of $20.00. The company’s shares closed last Wednesday at $4.57, close to its 52-week low of $4.01.
According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for scPharmaceuticals with a $21.25 average price target, implying a 388.5% upside from current levels. In a report issued on May 14, Leerink Partners also maintained a Buy rating on the stock with a $22.00 price target.
See the top stocks recommended by analysts >>
Andlauer Healthcare Group (ANDHF)
Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on Andlauer Healthcare Group today and set a price target of C$52.00. The company’s shares closed last Friday at $37.80.
According to TipRanks.com, Keywood is a 1-star analyst with an average return of
Currently, the analyst consensus on Andlauer Healthcare Group is a Moderate Buy with an average price target of $36.32, implying a 22.0% upside from current levels. In a report issued on May 6, TD Securities also maintained a Buy rating on the stock with a C$52.00 price target.
Roche Holding AG (RHHVF)
J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG today and set a price target of CHF210.00. The company’s shares closed last Wednesday at $248.24.
According to TipRanks.com, Vosser is a 5-star analyst with an average return of
Roche Holding AG has an analyst consensus of Hold, with a price target consensus of $285.91.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SCPH:
- scPharmaceuticals reports Q1 EPS (36c), consensus (44c)
- scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- scPharmaceuticals management to meet with Craig-Hallum
- SCPH Earnings this Week: How Will it Perform?
